



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

| | |
|----------------------|-----------------------|
| Application Number | 10/813,209 |
| Filing Date | March 29, 2004 |
| First Named Inventor | Hofmann, Gunter |
| Art Unit | 3763 |
| Examiner Name | Koharski, Christopher |

Sheet

1

of

2

Attorney Docket No: GTI-1360-CT

US PATENT DOCUMENTS

| Examiner Initial * | Cite No | Document Number | Publication Date | Name of Patentee or Applicant of Cited Document | Filing Date If Appropriate |
|--------------------|---------|-----------------|------------------|-------------------------------------------------|----------------------------|
| | 1 | 2,754,818 | 07 Jul 1956 | Scherer | |
| | 2 | 3,805,783 | 23 Apr 1974 | Ismash | |
| | 3 | 4,342,310 | 03 Aug 1982 | Lindmayer et al | |
| | 4 | 4,447,223 | 08 May 1984 | Kaye et al | |
| | 5 | 4,752,285 | 21 Jun 1988 | Petelenz et al | |
| | 6 | 5,013,293 | 07 May 1991 | Sibalis | |
| | 7 | 5,019,034 | 28 May 1991 | Weaver et al | |
| | 8 | 5,273,525 | 28 Dec 1993 | Hofmann | |
| | 9 | 5,389,069 | 14 Feb 1995 | Weaver | |
| | 10 | 5,468,223 | 21 Nov 1995 | Mir | |
| | 11 | 5,505,697 | 09 Apr 1996 | McKinnon et al | |
| | 12 | 5,506,125 | 09 Apr 1996 | McCabe et al | |
| | 13 | 5,547,467 | 20 Aug 1996 | Pliquett et al | |
| | 14 | 5,551,953 | 03 Sep 1996 | Lattin et al | |
| | 15 | 5,589,466 | 31 Dec 1996 | Felgner et al | |
| | 16 | 5,599,302 | 04 Feb 1997 | Lilley et al | |
| | 17 | 5,667,491 | 16 Sep 1997 | Pliquett et al | |
| | 18 | 5,702,359 | 30 Dec 1997 | Hofmann et al | |
| | 19 | 5,857,492 | 12 Jan 1999 | Haak et al | |
| | 20 | 5,993,434 | 30 Nov 1999 | Dev et al | |
| | 21 | 6,035,234 | 07 Mar 2000 | Riddle et al | |
| | 22 | 6,086,572 | 11 Jul 2000 | Johnson et al | |
| | 23 | 6,148,232 | 14 Nov 2000 | Avrahami | |
| | 24 | 6,192,270 | 20 Feb 2001 | Hofmann | |
| | 25 | 6,328,728 | 11 Dec 2001 | Holladay et al | |
| | 26 | 6,520,950 | 18 Feb 2003 | Hofmann et al | |
| | 27 | 2002/0102729 | 01 Aug 2002 | MacLaughlin et al | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of cited Document | T ² |
|--------------------|---------|-------------------------|------------------|-------------------------------------------------|----------------|
|--------------------|---------|-------------------------|------------------|-------------------------------------------------|----------------|

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | 28 | BOQUET et al, "Binding of triton X-100 to diphtheria toxin, crossreacting material 45, and their fragments," <i>Proc. Natl. Acad. Sci. USA</i> 73(12):4449-4453 (1976) | |
| | 29 | CECH, "Ribozymes and their medical implications," <i>J. Amer. Med. Assn.</i> 260:3030-3034 (1988) | |
| | 30 | DINH et al, "Upper and Lower Limits of Human Skin Electrical Resistance in Iontophoresis," <i>AIChE J.</i> 39:2011-2018 (1993) | |
| | 31 | DONNELLY et al., "DNA vaccines," <i>Annu. Rev. Immunol.</i> 15:617-648 (1997) | |

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-----------------------|
| Application Number | 10/813,209 |
| Filing Date | March 29, 2004 |
| First Named Inventor | Hofmann, Gunter |
| Art Unit | 3763 |
| Examiner Name | Koharski, Christopher |

Sheet

2

of

2

Attorney Docket No: GTI-1360-CT

| | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 32 | HASELOFF et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities," <i>Nature</i> 334:585-591 (1988) | |
| 33 | HELENE, "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides," <i>Anticancer Drug Design</i> 6(6):569-584 (1991) | |
| 34 | KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs," <i>Proc. Natl. Acad. Sci. USA</i> 95:12631-12636 (1998) | |
| 35 | McCULLOCH, "The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia," <i>Blood</i> 59:601-608 (1982) | |
| 36 | MAHER III, "Oligonucleotide-Directed DNA Triple-Helix Formation: An Approach to Artificial Repressors?," <i>Anti. Res and Dev.</i> 1:277-281 (1991) | |
| 37 | MARCUS-SEKURA, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression," <i>Anal. Bio.</i> 172:289-295 (1988) | |
| 38 | RICHMOND et al., "Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting," <i>J. Virol.</i> 72:9092-9100 (1998) | |
| 39 | ROBINSON et al., "Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations," <i>Nat. Med.</i> 5:526-534 (1999) | |
| 40 | TANG et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> 356:152-154 (1992) | |
| 41 | THORPE et al., "An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from <i>Saponaria officinalis</i> : potent antitumor effects in vitro and in vivo," <i>J. National Cancer Institute</i> 75:151-159 (1985) | |
| 42 | ULMER et al., "Heterologous protection against influenza by injection of DNA encoding a viral protein," <i>Science</i> 259:1745-1749 (1993) | |
| 43 | WEERATNA et al., "Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides," <i>Antisense Nucleic Acid Drug Dev.</i> 8(4):351-356 (1998) | |
| 44 | WEINTRAUB, "Antisense RNA and DNA," <i>Scientific American</i> 262:40-46 (1990) | |
| 45 | YEUNG et al., "Purification of three isolectins from root tubers of <i>trishoanthus kirilowii</i> (Tianhuafen)," <i>Intl. J. of Peptide Protein Res.</i> 27:325-333 (1985) | |

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached